Abstract: A surgery visualization system is described herein. The surgery visualization system includes a display monitor positioned in view of a surgeon and a support arm system including a first support arm and a second support arm. The first and second support arms are orientated such that the display monitor is visible to the surgeon between the first and second support arms. A 3D digital viewport coupled to the first support arm. A 3D digital microscope coupled to the second support arm. A computer system including a processor programmed to receive and process images from the 3D digital microscope and display the processed images on the 3D digital viewport and the display monitor.

Abstract: The present invention relates to certain pyrazolo[1,5a]pyrimidine compounds, to processes for their preparation, compositions comprising them and methods of using them. The compounds are useful in the treatment of cancer. Novel screening methods are also provided.

Abstract: The invention provides a method for detecting apoptosis in a myeloid cell comprising detecting an alteration in any one of: i) a Survivin polypeptide having an amino acid sequence as set out in SEQ ID NO: 1; ii) a polypeptide having at least 80% homology with i); iii) a nucleic acid encoding a polypeptide having the sequence set out in i) or ii); iv) a nucleic acid which hybridises under stringent conditions to the sequence set out in iii); or v) the complement of iii) or iv). The invention accordingly provides a method of modulating apoptosis in neutrophils by modulating Survivin gene expression and a method of treating inflammatory disease by modulating Survivin gene expression or function.

Abstract: The present invention relates to a method of indentifying an agent that modulates the function of an apoptosos-associated polypeptide having a sequence as set out in Table 1, the method comprising: (a) providing a sample containing an apoptosis-associated polypeptide having a sequence as set out in Table 1, and a candidate agent and incubating under conditions to permit binding of the candidate agent to the polypeptide; (b) measuring the binding of the apoptosis-associated polypeptide having a sequence as set out in Table 1 to the candidate agent in the sample; and (c) comparing the binding of the apoptosis-associated polypeptide having a sequence as set out in Table 1 to the candidate agent in the sample with the binding of the polypeptide having a sequence as set out in Table 1; wherein an increase in the binding of the apoptosis-associated polypeptide having a sequence as set out in Table 1 to the candidate agent in the sample relative to the binding of the apoptosis-associated polypeptide having a sequenc

Abstract: The present invention is in the field of molecular biology and genetics. More specifically, the invention relates to human ?N p73, a novel gene associated with apoptosis regulation. The present invention provides and includes nucleic acid molecules, proteins and antibodies associated with ?N p73 and methods utilizing such agents, for example in gene isolation, gene analysis, the production of transformed cell lines, and transgenic cells modified to over- or under-express ?N p73. Moreover, the present invention includes use of the agents of the invention for the diagnosis, prevention and treatment of diseases associated with decreases or increased apoptosis.

Abstract: The invention provides a method for detecting apoptosis in a cell comprising detecting a decrease in any one of: i) an ELAVL-1 (embryonic lethal, abnormal vision, Drosophila-like 1) polypeptide having an amino acid sequences as set out in SEQ ID NO: 1; ii) a polypeptide having at least 80% homology with i); iii) a nucleic acid encoding a polypeptide having the sequence set out in i) or ii); iv) a nucleic acid which hybridises under stringent conditions to the sequence set out in iii); or v) the complement of iii) or iv). The invention accordingly provides a method of modulating apoptosis by modulating ELAVL-1 gene expression and a method for identifying genes associated with ELAVL-1 gene expression and thus identifying other genes associated with apoptosis. The invention also provides a novel nucleic acid sequence encoding the promoter region for ELAVL-1.

Abstract: The present invention relates to methods of identifying an agent that modulates the function of an apoptosis-associated polypeptide having a sequence as set out in Table 1B. The invention also relates to methods of modulating apoptosis, diagnostic methods, arrays, kits and compositions based upon the apoptosis-associated polypeptides having sequences as set out in Table 1B and in FIG. 42.

Abstract: The present invention relates to methods of identifying an agent that modulates the function of an apoptosis-associated polypeptide having a sequence as set out in Table 1B. The invention also relates to methods of modulating apoptosis, diagnostic methods, arrays, kits and compositions based upon the apoptosis-associated polypeptides having sequences as set out in Table 1B.

Abstract: The present invention relates to a method for identifying a gene product which modulates the transition of a cell between a non-apoptopic state and an apoptopic state, comprising the steps of: (a) exposing the cell to an inhibitor of GM-CSF mediated inhibition of apoptosis; and (b) exposing the cell to one or more agents which increase tyrosine phosphorylation; and (c) C) placing the cell in conditions which permit it to undergo spontaneous apoptosis; and (d) monitoring the level(s) of expression of the one or more gene products in the cell; and (e) identifying gene product(s) whose expression has been increased, decreased or modified as a result of performing steps (a) to (d).

Abstract: The invention relates to a system for modelling ROS-induced apoptosis in a cell, said system comprising: a) the provision of a population of cells; b) the exposure of said cell population to one or more stimuli which lead the cell population to undergo ROS-induced apoptosis; c) optionally, the exposure of said cell population to one or more inhibitors of ROS-induced apoptosis; d) the analysis of gene expression in the cell population; and e) the assessment of the onset of apoptosis in said cell population; and methods for identifying genes associated with ROS-induced apoptosis using such a system.